IsoRay, Inc. Launches National Dual Therapy Study for High Risk Prostate Cancer Focusing on Company’s Cesium-131 Internal Radiation Isotope

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX: ISR), announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.